241 related articles for article (PubMed ID: 21287665)
1. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.
Crombé V; Salleron J; Savoye G; Dupas JL; Vernier-Massouille G; Lerebours E; Cortot A; Merle V; Vasseur F; Turck D; Gower-Rousseau C; Lémann M; Colombel JF; Duhamel A
Inflamm Bowel Dis; 2011 Oct; 17(10):2144-52. PubMed ID: 21287665
[TBL] [Abstract][Full Text] [Related]
2. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2009 Sep; 15(9):1295-301. PubMed ID: 19340881
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
[TBL] [Abstract][Full Text] [Related]
4. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
[TBL] [Abstract][Full Text] [Related]
5. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
[TBL] [Abstract][Full Text] [Related]
6. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T
Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474
[TBL] [Abstract][Full Text] [Related]
7. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study.
Biancone L; Petruzziello C; Orlando A; Kohn A; Ardizzone S; Daperno M; Angelucci E; Castiglione F; D'Incà R; Zorzi F; Papi C; Meucci G; Riegler G; Sica G; Rizzello F; Mocciaro F; Onali S; Calabrese E; Cottone M; Pallone F
Inflamm Bowel Dis; 2011 Mar; 17(3):758-66. PubMed ID: 20684009
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
9. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort.
Juillerat P; Sokol H; Froehlich F; Yajnik V; Beaugerie L; Lucci M; Burnand B; Macpherson AJ; Cosnes J; Korzenik JR
Inflamm Bowel Dis; 2015 Jan; 21(1):60-70. PubMed ID: 25517594
[TBL] [Abstract][Full Text] [Related]
12. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
[TBL] [Abstract][Full Text] [Related]
13. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
Fumery M; Jacob A; Sarter H; Michaud L; Spyckerelle C; Mouterde O; Savoye G; Colombel JF; Peyrin-Biroulet L; Gower-Rousseau C; Turck D;
J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):744-8. PubMed ID: 26000887
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic monitoring of infliximab therapy in Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
[TBL] [Abstract][Full Text] [Related]
16. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
17. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn's Disease: A Hospital-Based Cohort Study.
Park SH; Hwang SW; Kwak MS; Kim WS; Lee JM; Lee HS; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yoon YS; Yu CS; Kim JH; Yang SK
Dig Dis Sci; 2016 Jul; 61(7):2060-7. PubMed ID: 26971089
[TBL] [Abstract][Full Text] [Related]
20. Infliximab and pediatric stricturing Crohn's disease: a possible alternative to surgery? Experience of seven cases.
Gasparetto M; Corradin S; Vallortigara F; Cananzi M; Guariso G
Acta Gastroenterol Belg; 2012 Mar; 75(1):58-60. PubMed ID: 22567750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]